A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults with Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

  • Fedele, Pasquale (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

HREC Reference Number: HREC/84498/Alfred-2022
SSA Reference: SSA/84498/MonH-2023-372654(v1)
Monash Health Local Reference: RES-23-0000-290X
StatusActive
Effective start/end date22/05/23 → 21/05/28

Clinical Trial Phase

  • Phase I
  • Phase II